Oral presentation will detail consolidated results from 81 patients with steroid-resistant, gastrointestinal, acute Graft-versus-Host-Disease (GI-aGvHD) treated with MaaT013 as salvage therapy, as part of an ongoing Early Access Program (EAP).Poster will present detailed results from the Phase 1b clinical trial of M.
BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and.
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.
/PRNewswire/ Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address.